|
|
TLR4 agonist lipopolysaccharides |
|
Vaxjo ID |
306 |
|
Vaccine Adjuvant Name |
TLR4 agonist lipopolysaccharides |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
TLR4 agonist lipopolysaccharides (LPS) influences hepatocellular carcinoma cells by upregulating TLR4 mRNA and protein levels, activating NF-魏B and STAT3 signaling pathways, mediating the generation of inflammatory factors (IL-6, IL-8, TNF-伪), strengthening the proliferation ability of liver cancer cells, and promoting their transition from G1 to S stage. It can also induce liver cancer cell proliferation and multidrug resistance by activating the cyclooxygenase-2/prostaglandin signal axis and the STAT3 pathway. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Rat |
|
Function |
Human liver cancer cell lines HepG2, H7402, and PLC/PRF/5 were taken as models, and the expression of TLRs mRNA was detected by real time-polymerase chain reaction method semiquantitatively. WST-1 method was used to detect the influence of LPS on the proliferation ability of liver cancer cells |
| Related Vaccine(s) |
|
| References |
Gu et al., 2015: Gu J, Sun R, Shen S, Yu Z. The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer. OncoTargets and therapy. 2015; 8; 2215-2225. [PubMed: 26345468].
|
|
